Literature DB >> 17035507

The effect of intensive lipid lowering on coronary atheroma and clinical outcome.

Emma S Houslay, Jaydeep Sarma, Neal G Uren.   

Abstract

The association between raised plasma cholesterol and cardiovascular risk is well established, with consistent evidence associating LDL-cholesterol reduction with a reduction in primary and secondary cardiovascular events. It is believed that intensive lipid lowering may improve clinical outcomes further by acting to stabilise plaque and preventing plaque progression, ultimately reducing plaque vulnerability. However, it remains uncertain whether a continued clinical benefit occurs with intensive lipid lowering or if there is a threshold level below which no further benefit occurs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035507      PMCID: PMC1861387          DOI: 10.1136/hrt.2006.105676

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  22 in total

Review 1.  Prospective studies of C-reactive protein as a risk factor for cardiovascular disease.

Authors:  P M Ridker; P Haughie
Journal:  J Investig Med       Date:  1998-10       Impact factor: 2.895

2.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

Authors:  P M Ridker; N Rifai; M A Pfeffer; F M Sacks; L A Moye; S Goldman; G C Flaker; E Braunwald
Journal:  Circulation       Date:  1998-09-01       Impact factor: 29.690

3.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.

Authors:  Allen J Taylor; Lance E Sullenberger; Hyun J Lee; Jeannie K Lee; Karen A Grace
Journal:  Circulation       Date:  2004-11-10       Impact factor: 29.690

4.  Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.

Authors:  Michael J Koren; Donald B Hunninghake
Journal:  J Am Coll Cardiol       Date:  2004-11-02       Impact factor: 24.094

5.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

6.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

7.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

8.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.

Authors:  G Liuzzo; L M Biasucci; J R Gallimore; R L Grillo; A G Rebuzzi; M B Pepys; A Maseri
Journal:  N Engl J Med       Date:  1994-08-18       Impact factor: 91.245

9.  Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.

Authors:  S J Lewis; F M Sacks; J S Mitchell; C East; S Glasser; S Kell; R Letterer; M Limacher; L A Moye; J L Rouleau; M A Pfeffer; E Braunwald
Journal:  J Am Coll Cardiol       Date:  1998-07       Impact factor: 24.094

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.